What happens when HER2-Low Breast Cancer treatment stops working

When HER2-Low Breast Cancer Treatment Stops Working

This is an important question, and understanding your options when treatment becomes less effective is crucial for your care planning.

What "Treatment Stops Working" Means

When doctors say treatment has stopped working, they typically mean one of these situations:

• Disease progression: Imaging scans show the cancer is growing despite ongoing treatment
• Rising tumor markers: Blood tests show increasing levels of cancer markers (like CA 15-3)
• New symptoms: You develop new signs that suggest the cancer is advancing
• Plateau effect: The cancer was responding but has now stabilized and begun growing again

The Clinical Approach to HER2-Low Breast Cancer

According to NCCN Guidelines for Metastatic Breast Cancer, HER2-low disease (which includes IHC 1+ and 2+ tumors) has opened new treatment possibilities in recent years. Here's what's important to understand:

Why HER2-Low Matters

HER2-low breast cancers were historically considered "HER2-negative" and treated differently than HER2-positive cancers. However, research has shown these tumors DO express some HER2 protein—just at lower levels. This distinction has changed treatment options significantly.

Key Treatment Progression

First-line approach (initial treatment):

• For hormone receptor-positive (HR+) HER2-low: Endocrine therapy (hormone therapy) plus CDK4/6 inhibitors (drugs like palbociclib, ribociclib, or abemaciclib)
• For hormone receptor-negative (HR-) HER2-low: Chemotherapy-based approaches

When first-line treatment stops working, doctors typically consider:

1. Trastuzumab deruxtecan (T-DXd/Enhertu) - This is a major breakthrough for HER2-low disease. According to the webinar on Proteomic Testing for Cancer, this antibody-drug conjugate (ADC) showed significant benefit in HER2-low patients:

   • Overall survival of 24 months compared to 17 months for chemotherapy alone
   • FDA-approved specifically for HER2-low breast cancer
   • Works by attaching directly to HER2 proteins and delivering chemotherapy inside cancer cells

2. Alternative endocrine therapies - If you haven't exhausted hormone therapy options, switching to a different type may help

3. Different chemotherapy regimens - Changing the chemotherapy drugs or combinations

4. Clinical trials - Newer drug combinations or immunotherapy approaches

Important Biomarker Consideration

According to the CancerPatientLab webinar on Proteomic Testing, understanding your specific HER2 protein levels (not just IHC score) can be valuable:

• High HER2 expression (>750 amol/microgram): Opens more targeted therapy options
• Low HER2 expression: T-DXd becomes an increasingly important option
• Some patients benefit from dual HER2-targeted therapy (combining two different anti-HER2 drugs)

Questions to Ask Your Oncologist

When treatment stops working, bring these specific questions to your care team:

1. "What does the progression look like in my case—is it growing in existing sites or new areas?" (This affects treatment decisions)

2. "Have we confirmed my HER2 status with current testing, or should we retest?" (Tumors can change over time)

3. "Am I a candidate for T-DXd (Enhertu) or other HER2-targeted therapies?" (This is now standard consideration for HER2-low disease)

4. "What are the pros and cons of continuing hormone therapy versus switching to chemotherapy-based approaches?"

5. "Are there clinical trials I should consider at this point?"

6. "What's your timeline for reassessing if the next treatment is working?" (Helps you understand when to expect the next decision point)

The Bigger Picture

According to NCCN Guidelines, the approach to metastatic breast cancer emphasizes:

• Shared decision-making: Your preferences about treatment intensity matter
• Multiple treatment lines: Most patients will have options for several sequential treatments
• Individualized timing: The decision about when to switch treatments depends on your specific situation, performance status, and goals

The fact that HER2-low breast cancer is now recognized as a distinct category with targeted options like T-DXd represents real progress. Your oncologist will determine the best sequence based on what you've already received, how you tolerated it, and your current health status.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.